"目錄號: HY-15240

Protein Tyrosine Kinase/RTK-

DCC-2618 是一種有效的c-Kit和c-Met抑制劑，IC50值 <200 nM。

c-Kitc-Met/HGFR

相關產品

Sorafenib-Pexidartinib-Cabozantinib-Crizotinib-Imatinib Mesylate-Pazopanib-BMS 777607-Foretinib-Dovitinib-PHA-665752-Tivantinib-Savolitinib-INCB28060-Masitinib-LY2801653-

生物活性

Description

DCC-2618 is a potent inhibitor ofc-Kitandc-MetwithIC50s of <200 nM.

IC50& Target

IC50: <200 nM (c-Met), <200 nM (c-Kit), <2 μM (KDR), <10 μM (PDGFRα), <10 μM (PDGFRβ)[1]

In Vitro

DCC-2618 is a c-Kit and c-Met inhibitor extracted from patent 2010051373A1, compound example 45, has an IC50of <200 nM. DCC-2618 also inhibits KDR, PDGFR α and β with IC50s of <2 μM, <10 μM and <10 μM, respectively[1].

Clinical Trial

NCT02571036

Deciphera Pharmaceuticals LLC

Gastrointestinal Stromal Tumors-Aggressive Systemic Mastocytosis-Advanced Cancers

October 2015

Phase 1

View MoreCollapse

References

[1].Daniel L. Flynn, et al. Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities. WO 2010051373 A1